Back

Proteomics profiling reveals signaling pathways associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Genes and cardiomyopathies Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Charlotte Lee

Columbia University Medical Centre, New York (United States of America)

6 More presentations in this session

Presentation thumbnail
Family screening in dilated cardiomyopathy- qualifying screening and need for follow-up
Doctor C. Vissing (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Prognostic prediction of genotype versus phenotype in genetic cardiomyopathies
Doctor A. Paldino (Trieste, IT)
Abstract Slides
Presentation thumbnail
Mechano-energetic efficiency in patients with hypertrophic cardiomyopathy with and without sarcomeric mutations.
Doctor F. Borrelli (Napoly, IT)
Abstract Slides
Presentation thumbnail
A multi-modality, multi-parametric phenotyping study of transthyretin amyloid cardiomyopathy associated with the p.V142I TTR variant.
Doctor Y. Razvi (London, GB)
Abstract Slides
Presentation thumbnail
Different prognosis of ARVC patients between DSG2 and PKP2 variant carriers
Doctor K. Sonoda (Suita, JP)
Abstract Slides

Access the full session

Session thumbnail
Genes and cardiomyopathies

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources